Literature DB >> 26097514

Well-defined single polymer nanoparticles for the antibody-targeted delivery of chemotherapeutic agents.

D D Lane1, D Y Chiu1, F Y Su1, S Srinivasan1, H B Kern1, O W Press1, P S Stayton1, A J Convertine1.   

Abstract

Aqueous reversible addition-fragmentation chain transfer (RAFT) polymerization was employed to prepare a series of linear copolymers of N,N-dimethylacrylamide (DMA) and 2-hydroxyethylacrylamide (HEAm) with narrow Đ values over a molecular weight range spanning three orders of magnitude (103 to 106 Da). Trithiocarbonate-based RAFT chain transfer agents (CTAs) were grafted onto these scaffolds using carbodiimide chemistry catalyzed with DMAP. The resultant graft chain transfer agent (gCTA) was subsequently employed to synthesize polymeric brushes with a number of important vinyl monomer classes including acrylamido, methacrylamido, and methacrylate. Brush polymerization kinetics were evaluated for the aqueous RAFT polymerization of DMA from a 10 arm gCTA. Polymeric brushes containing hydroxyl functionality were further functionalized in order to prepare 2nd generation gCTAs which were subsequently employed to prepare polymers with a brushed-brush architecture with molecular weights in excess of 106 Da. These resultant single particle nanoparticles (SNPs) were employed as drug delivery vehicles for the anthracycline-based drug doxorubicin via copolymerization of DMA with a protected carbazate monomer (bocSMA). Cell-specific targeting functionality was also introduced via copolymerization with a biotin-functional monomer (bioHEMA). Drug release of the hydrazone linked doxorubicin was evaluated as function of pH and serum and chemotherapeutic activity was evaluated in SKOV3 ovarian cancer cells.

Entities:  

Year:  2015        PMID: 26097514      PMCID: PMC4470501          DOI: 10.1039/C4PY01250J

Source DB:  PubMed          Journal:  Polym Chem        ISSN: 1759-9954            Impact factor:   5.582


  32 in total

Review 1.  Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction.

Authors:  Sungwon Kim; Yunzhou Shi; Ji Young Kim; Kinam Park; Ji-Xin Cheng
Journal:  Expert Opin Drug Deliv       Date:  2010-01       Impact factor: 6.648

2.  Direct, controlled synthesis of the nonimmunogenic, hydrophilic polymer, poly(N-(2-hydroxypropyl)methacrylamide) via RAFT in aqueous media.

Authors:  Charles W Scales; Yulia A Vasilieva; Anthony J Convertine; Andrew B Lowe; Charles L McCormick
Journal:  Biomacromolecules       Date:  2005 Jul-Aug       Impact factor: 6.988

3.  Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells.

Authors:  Maria C Palanca-Wessels; Anthony J Convertine; Richelle Cutler-Strom; Garrett C Booth; Fan Lee; Geoffrey Y Berguig; Patrick S Stayton; Oliver W Press
Journal:  Mol Ther       Date:  2011-05-31       Impact factor: 11.454

4.  Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors.

Authors:  Christian Johannes Schmitt; Sascha Dietrich; Antony Dick Ho; Mathias Witzens-Harig
Journal:  Ann Hematol       Date:  2011-08-18       Impact factor: 3.673

5.  Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes.

Authors:  B Ríhová; T Etrych; M Pechar; M Jelínková; M Stastný; O Hovorka; M Kovár; K Ulbrich
Journal:  J Control Release       Date:  2001-07-06       Impact factor: 9.776

Review 6.  Polymeric micelles in anticancer therapy: targeting, imaging and triggered release.

Authors:  Chris Oerlemans; Wouter Bult; Mariska Bos; Gert Storm; J Frank W Nijsen; Wim E Hennink
Journal:  Pharm Res       Date:  2010-08-20       Impact factor: 4.200

7.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

Authors:  M E R O'Brien; N Wigler; M Inbar; R Rosso; E Grischke; A Santoro; R Catane; D G Kieback; P Tomczak; S P Ackland; F Orlandi; L Mellars; L Alland; C Tendler
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

8.  Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study.

Authors:  Joseph A Sparano; Anatoly N Makhson; Vladimir F Semiglazov; Sergei A Tjulandin; Olga I Balashova; Igor N Bondarenko; Natalia V Bogdanova; George M Manikhas; Gennadiy P Oliynychenko; Valery A Chatikhine; Sen H Zhuang; Liang Xiu; Zhilong Yuan; Wayne R Rackoff
Journal:  J Clin Oncol       Date:  2009-08-17       Impact factor: 44.544

9.  Development of a novel endosomolytic diblock copolymer for siRNA delivery.

Authors:  Anthony J Convertine; Danielle S W Benoit; Craig L Duvall; Allan S Hoffman; Patrick S Stayton
Journal:  J Control Release       Date:  2008-10-17       Impact factor: 9.776

Review 10.  Potent antibody drug conjugates for cancer therapy.

Authors:  Peter D Senter
Journal:  Curr Opin Chem Biol       Date:  2009-05-04       Impact factor: 8.822

View more
  2 in total

1.  ATRP Synthesis of Sunflower Polymers using Cyclic Multimacroinitiators.

Authors:  Hua Wei; Christine E Wang; Nicholas Tan; Andrew J Boydston; Suzie H Pun
Journal:  ACS Macro Lett       Date:  2015-08-17       Impact factor: 6.903

Review 2.  Polymer nanostructures synthesized by controlled living polymerization for tumor-targeted drug delivery.

Authors:  Christine E Wang; Patrick S Stayton; Suzie H Pun; Anthony J Convertine
Journal:  J Control Release       Date:  2015-09-02       Impact factor: 9.776

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.